[1]章惠玲,宋梦林,丰昊,等.参萸养心胶囊治疗慢性心力衰竭元气亏虚证临床研究[J].陕西中医,2025,46(7):914-917,928.[doi:DOI:10.3969/j.issn.1000-7369.2025.07.010]
　ZHANG Huiling,SONG Menglin,FENG Hao,et al.Clinical study on treatment of chronic heart failure with Qi deficiency syndrome type by Shenyu Yangxin capsules[J].,2025,46(7):914-917,928.[doi:DOI:10.3969/j.issn.1000-7369.2025.07.010]
点击复制

参萸养心胶囊治疗慢性心力衰竭元气亏虚证临床研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年7期
页码:
914-917,928
栏目:
临床研究
出版日期:
2025-07-05

文章信息/Info

Title:
Clinical study on treatment of chronic heart failure with Qi deficiency syndrome type by Shenyu Yangxin capsules
作者:
章惠玲1; 宋梦林1; 丰昊2; 刘平1; 罗钢1
（1.西南医科大学附属中医医院,四川 泸州 646699；2.西南医科大学,四川 泸州 646699）
Author(s):
ZHANG Huiling1; SONG Menglin1; FENG Hao2; LIU Ping1; LUO Gang1
(1.The Affiliated Traditional Chinese Medicine Hospital,Southwest Medical University,Luzhou 646699,China；2.Southwest Medical University,Luzhou 646699,China)
关键词:
慢性心力衰竭; 元气亏虚证; 参萸养心胶囊; 中医证候积分; 心功能; 生活质量
Keywords:
Chronic heart failure; Qi deficiency syndrome; Shenyu Yangxin capsules; Traditional Chinese medicine syndrome score; Heart function; Quality of life
分类号:
R 541
DOI:
DOI:10.3969/j.issn.1000-7369.2025.07.010
文献标志码:
A
摘要:
目的：评估参萸养心胶囊治疗慢性心力衰竭（CHF）元气亏虚证临床疗效。方法：纳入148例CHF元气亏虚证患者，按1∶1比例分为试验组、对照组。试验组采用西医常规基础治疗及参萸养心胶囊干预；对照组采用西医常规基础治疗及安慰剂，两组疗程均28 d。观察比较两组临床疗效、中医证候要素积分、脑钠肽（BNP）、心脏彩超指标、6分钟步行距离（6MWD）、明尼苏达心衰生活质量积分（MLHFQ）等。结果：治疗后试验组临床总有效率90.5%（67/74）高于对照组总有效率87.8%（65/74），差异无统计学意义（P＞0.05）。治疗后两组中医证候要素积分、BNP水平较治疗前下降，且试验组降低幅度更显著（均P＜0.05）。治疗后试验组左心室射血分数较本组治疗前升高，试验组左心室收缩末期内径较对照组降低（均P＜0.05）。治疗后与对照组相比，试验组6MWD较高，MLHFQ评分较低（P＜0.05）。结论：参萸养心胶囊可有效缓解慢性心力衰竭元气亏虚证患者临床症状，改善心功能，提高运动耐力及生活质量。
Abstract:
Objective:Evaluate clinical efficacy of Shenyu Yangxin capsules in treating chronic heart failure (CHF) with Qi deficiency syndrome.Methods:148 CHF patients with Qi deficiency syndrome were included and divided into experimental group and control group in 1∶1 ratio.The experimental group received conventional western medicine basic treatment plus Shenyu Yangxin capsule intervention,while the control group received conventional western medicine basic treatment plus placebo treatment,with treatment course of 28 days for both groups.Observe and compare clinical efficacy,traditional Chinese medicine symptom score,brain natriuretic peptide (BNP),cardiac ultrasound indicators,6-minute walking distance (6MWD),minnesota heart failure quality of life score (MLHFQ) and other indicators between two groups.Results:There was no statistically significant difference in the clinical effective rate between the two groups after treatment (P＞0.05),the total clinical effective rate of the experimental group was 90.5% (67/74) higher than that in the control group 87.8%（65/74）.Compared with before treatment,the scores of traditional Chinese medicine syndrome elements and BNP levels in both groups significantly decreased after treatment,and the experimental group was lower than the control group,statistically significant differences(P＜0.05).After treatment,the left ventricular ejection fraction (LVEF) in the experimental group increased significantly compared to before treatment,and left ventricular end systolic diameter(LVESD) in the experimental group decreased significantly compared to the control group (all P＜0.05).After treatment,compared with the control group,the experimental group had higher 6MWD and lower MLHFQ scores,differences statistically significant(all P＜0.05).Conclusion:Shenyu Yangxin capsules can effectively alleviate the clinical symptoms of chronic heart failure patients with Qi deficiency syndrome,improve their heart function,enhance exercise endurance,and improve their quality of life.

参考文献/References:

[1]HWANG S Y,KIM S H,UHM I A,et al.Prognostic implications for patients after myocardial infarction:An integrative literature review and in-depth interviews with patients and experts[J].BMC Cardiovasc Disord,2022,22(1):348.
[2]HEIDENREICH P A,BOZKURT B,AGUILAR D,et al.2022 AHA/ACC/HFSA guideline for the management of heart failure:A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J].Circulation,2022,145(18):e895-e1032.
[3]刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》要点解读[J].中国心血管杂志,2024,29(4):305-324.
[4]蒋沈华,虞坚尔,冯其茂.中药保护线粒体功能在慢性心力衰竭治疗中的应用进展[J].陕西中医,2024,45(7):1006-1009.
[5]朱杰,林兆奋,胡聃,等.中西医结合治疗慢性心力衰竭研究进展[J].陕西中医,2020,41(9):1342-1344.
[6]孙君怡,薛睿聪,梁玮昊,等.慢性心力衰竭的诊疗现状[J].自然杂志,2022,44(2):126-148.
[7]PAULUS W J,TSCHOPE.A novel paradigm for heart failure with preserved ejection fraction:Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J].J Am coll Cardiol，2013,62(4):263-271.
[8]金善子,孙晓雨,刘月.慢性心力衰竭中西医结合治疗的研究进展[J].世界复合医学,2024,10(6):195-198.
[9]张凯清,韩景波,饶亚平,等.中医药治疗慢性心力衰竭的研究进展[J].中医临床研究,2024,16(30):78-81.
[10]杜丽丽,宋忠敏,刘静,等.中西医治疗慢性心力衰竭的研究进展[J].中国社区医师,2024,40(19):7-9.
[11]江玉,江花,王倩,等.玄府理论研究现状[J].中医杂志,2016,57(20):1790-1794.
[12]董丽,江云东,杨思进,等.基于“络病-玄府”探讨糖尿病心肌病冠脉微循环病变[J].中国中医基础医学杂志,2020,26(5):633-668.
[13]董丽,李波,杨思进,等.基于玄府理论探讨清心通玄法在病毒性心肌炎的运用[J].泸州医学院学报,2014,37(4):396-397.
[14]连妍洁,李明轩,刘红旭,等.基于“玄府-气液-络脉”探讨心力衰竭的中医证治[J].中医杂志,2023,64(6):641-645.
[15]ZHANG C,ZHU Y,WANG M,et al.Comparison of chemical composition between imitation wild and transplanted astragali radix and their therapeutic effects on heart failure[J].J Ethnopharmacol，2024,337(1):118827.
[16]LU C,LI H,WANG X,et al.Investigating the mechanism of Chinese medicine formula AACO against chronic heart failure by network pharmacology analysis and experimental validation[J].Altern Ther Healthm，2024,30(11):354-368.
[17]HUANG Y,LIU Q,LIU M,et al.System pharmacology-based determination of the functional components and mechanisms in chronic heart failure treatment:An example of Zhenwu decoction[J].J Biomol Structdyn，2023,42(23):12935-12953.
[18]罗钢,杨廷富,杨思进.参萸养心胶囊抗心肌纤维化作用机制[J].西南医科大学学报,2022,45(3):256-261.
[19]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[20]国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002：77-84．
[21]毛静远,朱明军.慢性心力衰竭中医诊疗专家共识[J].中医杂志,2014,55(14):1258-1260.
[22]中华中医药学会慢性心力衰竭中医诊疗指南项目组.慢性心力衰竭中医诊疗指南(2022年)[J].中医杂志,2023,64(7):743-756.
[23]中华医学会，中华医学会临床药学分会，中华医学会杂志社，等.慢性心力衰竭基层合理用药指南[J].中华全科医师杂志,2021,20(1):42-49.
[24]陈可冀,吴宗贵,朱明军,等.慢性心力衰竭中西医结合诊疗专家共识[J].中国中西医结合杂志,2016,36(2):133-141.
[25]陈泽瑶,陈家祈,张琦,等.白虎加人参汤治疗2型糖尿病Meta分析[J].陕西中医,2024,45(7):989-994.
[26]童存存,赵明君,周端,等.当代中医名家辨治慢性心力衰竭经验撷英[J].陕西中医,2011,32(9):1269-1271.
[27]LO S H,HSU C T,NIU H S,et al.Ginsenoside Rh2 improves cardiac fibrosis via PPARδ-STAT3 signaling in type 1-like diabetic rats[J].Int J Mol Sci,2017,18(7):1364.
[28]DU Y,HAN J B,ZHANG H X,et al.Kaempferol prevents against Ang Ⅱ-induced cardiac remodeling through attenuating Ang Ⅱ-induced inflammation and oxidative stress[J].J Cardiovasc Pharmacol,2019,74(4):326-335.

相似文献/References:

[1]杨自生,金 琪,简立国.参苓养心汤治疗慢性心衰的疗效及对心功能、活动耐力、 NTProBNP、hsCRP的影响*[J].陕西中医,2019,(2):167.
　YANG Zisheng,JIN Qi,JIAN Liguo..The effect of Shenling Yangxin decoction on chronic heart failure and its effect on cardiac function，activity endurance，NTProBNP and hsCRP[J].,2019,(7):167.
[2]孙 哲,杨 默,石宗华.丹参多酚酸盐与丹参酮治疗慢性心力衰竭临床研究[J].陕西中医,2019,(5):591.
　SUN Zhe,YANG Mo,SHI Zonghua..Clinical effect and mechanism of salvianolate and Tanshinone in the treatment of chronic heart failure[J].,2019,(7):591.
[3]向宗兴,拓 文,仇卫峰,等.黄芪保心汤配合西药治疗慢性心力衰竭临床研究*[J].陕西中医,2019,(8):1085.
　XIANG Zongxing,TUO Wen,QIU Weifeng,et al.Clinical value of Huangqi Baoxin decoction combined with western medicine in the treatment of chronic heart failure[J].,2019,(7):1085.
[4]尚加芬.参芪附仙饮联合盐酸曲美他嗪片辨治慢性心力衰竭心肾阳虚证临床研究[J].陕西中医,2020,(1):38.
[5]陈宗伟,沈志涛,郑振国,等.芪苈强心胶囊配合保元汤加减治疗慢性心力衰竭临床研究*[J].陕西中医,2020,(2):191.
　CHEN Zongwei,SHEN Zhitao,ZHENG Zhenguo,et al.Observation on the effect of Qili Qiangxin capsules assist Baoyuan decoction in the treatment of chronic heart failure[J].,2020,(7):191.
[6]凌 望,孙思明,王璐玲,等.温阳益气活血方改善慢性心力衰竭患者生活质量临床研究*[J].陕西中医,2020,(5):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
　LING Wang,SUN Siming,WANG Luling,et al.A Study on the quality of life about Wenyang Yiqi Huoxue therapy in the treatment of chronic heart failure[J].,2020,(7):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
[7]朱 杰,林兆奋△,胡 聃,等.中西医结合治疗慢性心力衰竭研究进展*[J].陕西中医,2020,(9):1342.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.046]
[8]刘 薇,张玉焕,李 争.芪参益气滴丸对老年气虚血瘀型心力衰竭患者心肌保护、炎症状态的影响[J].陕西中医,2021,(1):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
　LIU Wei,ZHANG Yuhuan,LI Zheng.Effects of Qishen Yiqi dropping pills on myocardial protection,inflammatory state and serum cell adhesion molecule level in elderly patients with heart failure caused by qi deficiency and blood stasis[J].,2021,(7):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
[9]黄光明.理中汤加减治疗慢性心力衰竭及对患者血清BNP、IL-10及NOS水平的影响研究[J].陕西中医,2021,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
　HUANG Guangming.Modified Lizhong decoction on clinical symptoms and levels of serum BNP,IL-10 and NOS in patients with chronic heart failure[J].,2021,(7):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
[10]胡 芳,谭明娜,谭小娥,等.加味五苓散联合西药治疗慢性心力衰竭疗效及对患者心功能、纤维化指标、炎性因子水平的影响[J].陕西中医,2021,(2):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]
　HU Fang,TAN Mingna,TAN Xiao'e,et al.Effects of modified Wuling powder combined with western medicine on levels of cardiac function,fibrosis indicators and inflammatory factors in patients with chronic heart failure[J].,2021,(7):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]

备注/Memo

备注/Memo:
国家中医药管理局中医药创新团队及人才支持计划项目（ZYYCXTD-C-202207）；四川省科技厅项目（2022YFS0618）；四川省中医药管理局面上项目（2023MS451）
更新日期/Last Update: 2025-07-09